Roche began shipping its Axelios 1 next-generation sequencing platform commercially, targeting accuracy, speed, flexibility, scalability, and cost efficiency. The company said the rollout starts this week with initial focus on North America, Europe, and Asia-Pacific. Axelios 1 is positioned as a direct attempt to challenge Illumina’s installed base dominance, targeting bottlenecks in genomics where throughput and cost often constrain adoption. For sequencing buyers and biotech developers, the immediate question will be real-world performance and integration into existing workflows, including turnaround time and run-to-run consistency across clinical and research laboratories.